Navigation Links
Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
Date:12/2/2009

LONDON, Dec. 2 /PRNewswire-FirstCall/ -- Increasing genomic knowledge will lead to the development of improved therapies to treat lifestyle disorders. In the near future, the European lifestyle disorders therapeutics market is set to witness enhanced therapies and novel drugs to treat such conditions and reduce the risk of co-morbidities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.pharma.frost.com), European Lifestyle Disorders Therapeutics Market, finds that the European obesity therapeutics market and European erectile dysfunction therapeutics market earned revenues of $668.1 million and $1234.2 million, respectively, in 2008 and estimates this to reach $1158.1 million and $2,168.2 million in 2015, respectively.

"The future is likely to witness improved therapies and novel drugs to treat lifestyle disorders and lower the risk of co-morbidities," notes Frost & Sullivan Programme Leader Shabeer Hussain. "However, the lack of investment in the current financial climate has dampened the development of newer therapies and technologies, while presenting a major challenge for small biotechnology companies."

As preventive care and personalised medicine come to the fore, more companies are venturing into lifestyle disorders therapeutics. These new developments are likely to present attractive investment opportunities to large biopharmaceutical companies.

Differing regulations are having an impact on drug launches; less price-controlled markets generally witness quicker launches while it takes longer in more regulated markets.

"With the increase in demand for new therapies, the degree of competition among pharmaceutical companies is also intensifying," says Hussain. "However, the requirement of high initial investments against the backdrop of the global economic slowdown and heightened cost containment measures, have led to temporary or complete halt in R&D of new drugs."

Nevertheless, the scenario is optimistic. With advancements in drug discovery, especially in the field of genomics, proteomics and chemical libraries, drug companies are exercising tremendous efforts to bring out novel therapies for lifestyle disorders. This is likely to attract more investments in the future.

"The EU healthcare system should encourage the development of drugs for lifestyle disorders through its healthcare policy by introducing clear reimbursement policies," advises Hussain. "Efforts should also be made to ensure a transparent, EU-wide harmonisation of regulatory policy and an enhanced approval process for lifestyle disorders therapeutics."

If you are interested in more information about this study, please send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

European Lifestyle Disorders Therapeutics Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Vaccines Market, European Orphan Drugs Market and, Global Diabetes Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

European Lifestyle Disorders Therapeutics Market

M3F8



Contact:
Katja Feick
Corporate Communications - Europe
P: +49 (0) 69 7703343
E: katja.feick@frost.com

http://www.frost.com


SOURCE Frost & Sullivan


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers identify role of gene in tumor development, growth and progression
2. HCA Names Joe Sowell Senior Vice President & Chief Development Officer
3. Findings that should speed the development of drugs for Parkinsons disease
4. Nuvo research provides WF10 licensing and development update
5. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
6. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
7. Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource
8. Developmental drug may help bone fractures heal after radiation exposure
9. Martel Instruments Expands Its Custom Printer Solutions Business in North America; Liz Peirce Named Director of North American Business Development
10. Therap Services to Host Conference on Electronic Documentation, Electronic Signatures and Electronic Health Records for the Developmental Disabilities Community
11. UCSF diabetes, brain tumor stem cell grants to drive development of therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology: